Drug Pipeline & Clinical Insights – November 2026

A closer look at recent drug approvals and what they mean for treatment options, member care, and pharmacy benefit costs.

  • 2 Min read

  • November 10, 2026

Clinical Insights
LucyRx Clinical Insights November

Key Highlights

  • 2 key new drug approvals: HIBSAGO (bepirovirsen) offers some adults with chronic hepatitis B the possibility of stopping long-term medication; Juvmo (tavapadon) introduces a new approach to managing movement symptoms in adults with Parkinson’s disease. 
  • This month focuses on new treatment approaches: These recent approvals expand treatment options, with important considerations for treatment eligibility, cost, access, and monitoring. 
Key New Drug Approvals 

HIBSAGO (bepirovirsen) 

Approval Date: 10/20/2026
Cost*: U.S. list price not verified 

Key Considerations: 
  • First treatment of its kind for certain adults with chronic hepatitis B who do not have cirrhosis (advanced liver scarring). HIBSAGO is added to existing antiviral therapy after at least six months of treatment and requires specific blood test results. 
  • It is given as injections under the skin for up to 24 weeks. Existing antiviral medication continues during treatment and for at least 24 weeks afterward; only patients who meet specific criteria may stop medication under medical supervision. 
  • In clinical trials, 19% of treated patients achieved a functional cure, meaning the virus remained controlled 24 weeks after stopping all hepatitis B treatment. This does not mean the virus is completely eliminated. 
  • The drug carries a Boxed Warning for serious liver reactions and low platelet counts that can cause severe bleeding. Regular blood tests and provider follow-up are required. 

LucyRx Perspective: HIBSAGO could offer a path away from long-term medication for some patients, but not everyone will qualify or respond. Careful review of treatment eligibility, safety monitoring, and pricing will be central to evaluating its value.

Juvmo (tavapadon)  

Approval Date: 09/25/2026
Cost*: ~$4,900 per month 

Key Considerations: 
  • Once-daily oral treatment for Parkinson’s disease in adults, used alone or with levodopa to help manage movement symptoms. 
  • Targets different dopamine receptors (D1/D5) than most existing dopamine agonists. This offers a new treatment approach, but a different mechanism does not by itself establish better symptom control or fewer side effects. 
  • Dosing is gradually adjusted to the individual, with maintenance doses of 5 mg, 10 mg, or 15 mg taken orally once daily.  

LucyRx Perspective: Juvmo adds another option in a market with many established generic treatments. Its price is higher than other branded oral carbidopa/levodopa and dopamine agonist therapies, making symptom improvement and tolerability important considerations when assessing its value.

*Cost: List price is provided for general reference and does not reflect rebates, discounts, insurance coverage, copay support, or actual plan or member cost.

Tags

Drug Pipeline Pharmacy benefits specialty pharmacy

Recommended Reads

Benefits professionals in a meeting reviewing pharmacy benefit strategy and plan options for employer clients

Five Pharmacy Benefit Questions Every TPA Should Be Ready to Answer in 2027

Pharmacy now accounts for 25% of employer healthcare spending, so employers are pressing TPAs for clearer answers on cost, GLP-1s, control and implementation. This post outlines five questions to prepare for before the next RFP or renewal.
TPA and PBM partnership discussion focused on integrating pharmacy benefits into the broader employer health plan

Making More Pharmacy Benefit Choice Work for TPAs and Their Clients

TPAs are being asked to help employers make sense of more pharmacy benefit options, but they do not need to take on PBM integration work. This article explains how clear responsibilities, useful data, and an accountable PBM partnership can strengthen client service.
Business benefits professionals reviewing pharmacy benefit options and partnership requirements for employer health plans.

What Makes a Pharmacy Benefit Solution Easier for TPAs to Stand Behind?

Third-party administrators put their own client relationships at stake when recommending a pharmacy benefit manager. Learn which capabilities help TPAs evaluate PBM partners, explain benefit strategies confidently and maintain accountability from implementation through renewal.

When Women’s Health Reaches the Prescription, the Pharmacy Benefit Still Has Work to Do

Women’s health programs can improve clinical access, but prescription barriers can still interrupt treatment. Employers and benefits leaders should evaluate affordability, coverage, medication availability and how quickly access problems are resolved.
Benefits professionals reviewing pharmacy benefit contract terms, data access and implementation requirements to assess how much control employers have over their PBM strategy.

PBM Flexibility Is Not the Same as Control: What TPAs Should Test

Pharmacy benefit options have limited value if contract restrictions or operational barriers prevent employers from using them. This article outlines how TPAs can assess decision-making information, contractual rights and implementation capabilities before recommending a PBM.
Benefits and implementation teams reviewing a PBM transition plan, data requirements and go-live responsibilities before an employer pharmacy benefit launch.

Implementation Is Part of the Sale: What TPAs Should Test Before Recommending a PBM

A PBM transition can put a TPA’s client relationship at risk if eligibility errors, prescription disruptions or unclear responsibilities emerge at go-live. This checklist outlines five areas TPAs should test before recommending a PBM to an employer.
Employer benefits leader evaluating specialty pharmacy performance, costs, access, and member outcomes

How Should a Specialty Pharmacy Earn Its Role?

Specialty pharmacy can materially affect employer plan costs, access, and treatment continuity. This article outlines the measures benefits leaders can use to evaluate pharmacy channels based on evidence rather than affiliation.

Projected Savings vs. Realized Savings: What Employers Should Ask

Employers need to know whether a pharmacy savings figure represents an opportunity or an actual result. This article explains how to evaluate savings methodology, assumptions, and outcomes.
GLP-1 medication representing employer coverage and cost decisions

A Better Way to Think About GLP-1 Strategy

GLP-1 coverage no longer has to be an all-or-nothing decision. Employers can evaluate access, clinical support, costs, and benefit visibility to build a strategy that works for their plan and the people who rely on it.
Woman with glucose monitor

Diabetes Affordability is About More Than One Prescription

Diabetes affordability extends beyond insulin. Learn how employers can evaluate medication costs, GLP-1s, monitoring devices, coverage rules, and member support across the full diabetes regimen.
PreviousNext
Benefits professionals in a meeting reviewing pharmacy benefit strategy and plan options for employer clients

Five Pharmacy Benefit Questions Every TPA Should Be Ready to Answer in 2027

Pharmacy now accounts for 25% of employer healthcare spending, so employers are pressing TPAs for clearer answers on cost, GLP-1s, control and implementation. This post outlines five questions to prepare for before the next RFP or renewal.
TPA and PBM partnership discussion focused on integrating pharmacy benefits into the broader employer health plan

Making More Pharmacy Benefit Choice Work for TPAs and Their Clients

TPAs are being asked to help employers make sense of more pharmacy benefit options, but they do not need to take on PBM integration work. This article explains how clear responsibilities, useful data, and an accountable PBM partnership can strengthen client service.
Business benefits professionals reviewing pharmacy benefit options and partnership requirements for employer health plans.

What Makes a Pharmacy Benefit Solution Easier for TPAs to Stand Behind?

Third-party administrators put their own client relationships at stake when recommending a pharmacy benefit manager. Learn which capabilities help TPAs evaluate PBM partners, explain benefit strategies confidently and maintain accountability from implementation through renewal.

When Women’s Health Reaches the Prescription, the Pharmacy Benefit Still Has Work to Do

Women’s health programs can improve clinical access, but prescription barriers can still interrupt treatment. Employers and benefits leaders should evaluate affordability, coverage, medication availability and how quickly access problems are resolved.
Benefits professionals reviewing pharmacy benefit contract terms, data access and implementation requirements to assess how much control employers have over their PBM strategy.

PBM Flexibility Is Not the Same as Control: What TPAs Should Test

Pharmacy benefit options have limited value if contract restrictions or operational barriers prevent employers from using them. This article outlines how TPAs can assess decision-making information, contractual rights and implementation capabilities before recommending a PBM.
Benefits and implementation teams reviewing a PBM transition plan, data requirements and go-live responsibilities before an employer pharmacy benefit launch.

Implementation Is Part of the Sale: What TPAs Should Test Before Recommending a PBM

A PBM transition can put a TPA’s client relationship at risk if eligibility errors, prescription disruptions or unclear responsibilities emerge at go-live. This checklist outlines five areas TPAs should test before recommending a PBM to an employer.
Employer benefits leader evaluating specialty pharmacy performance, costs, access, and member outcomes

How Should a Specialty Pharmacy Earn Its Role?

Specialty pharmacy can materially affect employer plan costs, access, and treatment continuity. This article outlines the measures benefits leaders can use to evaluate pharmacy channels based on evidence rather than affiliation.

Projected Savings vs. Realized Savings: What Employers Should Ask

Employers need to know whether a pharmacy savings figure represents an opportunity or an actual result. This article explains how to evaluate savings methodology, assumptions, and outcomes.
GLP-1 medication representing employer coverage and cost decisions

A Better Way to Think About GLP-1 Strategy

GLP-1 coverage no longer has to be an all-or-nothing decision. Employers can evaluate access, clinical support, costs, and benefit visibility to build a strategy that works for their plan and the people who rely on it.
PreviousNext

LucyRx is an independent, modern pharmacy benefit manager with the scale of an enterprise serving more than 9 million members nationwide.

Follow us

Linkedin Linkedin Tiktok Tiktok Instagram Instagram
URAC Accreditation

Copyright © 2026 by LucyRx. All Rights Reserved | Privacy Policy | Terms of Use | Members Rights

Five Pharmacy Benefit Questions Every TPA Should Be Ready to Answer in 2027Benefits professionals in a meeting reviewing pharmacy benefit strategy and plan options for employer clients

Download the PBM Reform Readiness Checklist

Download the GLP-1 Planning Checklist